http://www.arrowres.com/ Arrowhead Research Corp.: Nanotech with a point en-us Copyright 2005, Arrowhead Research Corporation Thursday, 12 August 2010 Thursday, 12 August 2010 60 http://www.arrowres.com/images/links/logo_about1.gif http://www.arrowres.com/ 100 88 Arrowhead Research Corp.: Nanotech with a point http://www.arrowheadresearch.com/publications/august19_2010.html PASADENA, Calif. — August 19, 2010 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Mauro Ferrari has joined the Company’s Board of Directors. Mon, 19 Aug 2010 11:00:00 PST http://www.arrowheadresearch.com/publications/august16_2010.html PASADENA, Calif. — August 16, 2010 — Arrowhead Research Corporation (Nasdaq: ARWR) announced today that Dr. Mauro Ferrari, Chair of Arrowhead’s Scientific Advisory Board, has been named the President and CEO of The Methodist Hospital Research Institute. Mon, 16 Aug 2010 12:00:00 PST http://www.arrowheadresearch.com/publications/august12_2010.html PASADENA, Calif. – August 12, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 third quarter ended June 30, 2010. “In the third quarter, we continued to advance our late-stage subsidiaries and build on the momentum we began early in the calendar year,” said Christopher Anzalone, Arrowhead’s CEO. Thursday, 12 Aug 2010 12:20:00 PST http://www.arrowheadresearch.com/publications/august10_2010.html PASADENA, Calif. — Arrowhead Research Corporation (NASDAQ: ARWR)today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. Tue, 10 Aug 2010 12:00:00 PST http://www.arrowheadresearch.com/publications/august5_2010.html PASADENA, Calif. — August 5, 2010 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2010 third quarter ended June 30, 2010, on Thursday, August 12, 2010, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Thu, 5 Aug 2010 12:30:00 PST http://www.arrowheadresearch.com/publications/june23_2010.html Pasadena, CA – June 23, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has closed its previously announced registered direct offering of 6.6 million shares of common stock and warrants to purchase 3.3 million shares of common stock. Wed, 23 Jun 2010 12:00:00 PST http://www.arrowheadresearch.com/publications/june17_2010.html Pasadena, CA – June 17, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced and received firm commitments for a registered direct offering to raise $8.65 million through the sale of 6.6 million shares of its common stock, and warrants to purchase 3.3 million shares of common stock. Tue, 17 Jun 2010 11:30:00 PST http://www.arrowheadresearch.com/publications/june15_2010.html PASADENA, Calif. –June 15, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Annual Meeting of Stockholders will be held on Wednesday, June 16, 2010 at 10:00 am PT at the Sheraton Pasadena, 303 E. Cordova Street, Pasadena, CA. Wed, 15 Jun 2010 12:25:00 PST http://www.arrowheadresearch.com/publications/june14_2010.html PASADENA, Calif. –June 14, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will join the Russell Microcap® Index when Russell Investments reconstitutes its family of U.S. indexes, according to a preliminary list of additions posted June 11 on www.russell.com. Mon, 14 Jun 2010 11:00:00 PST http://www.arrowheadresearch.com/publications/june7_2010.html PASADENA, Calif.—June 7, 2010—Arrowhead Research Corporation (Nasdaq: ARWR) announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Mon, 7 Jun 2010 9:30:00 PST http://www.arrowheadresearch.com/publications/june01_2010.html PASADENA, Calif. - June 1, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that interim data from the phase 1 clinical trial conducted by its majority-owned subsidiary, Calando Pharmaceuticals, will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. Tue, 1 Jun 2010 9:30:00 PST http://www.arrowheadresearch.com/publications/may28_2010.html PASADENA, Calif. – May 28, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Noble Financial Sixth Annual Equity Conference at 10:30 a.m. EDT on June 8, 2010, at the Hard Rock Hotel in Hollywood, Florida. Wed, 28 May 2010 8:15:00 PST http://www.arrowheadresearch.com/publications/may27_2010.html PASADENA, Calif. – May 27, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that two articles of interest to Arrowhead stockholders appeared in the Houston Chronicle this week. Wed, 27 May 2010 11:10:00 PST http://www.arrowheadresearch.com/publications/may19_2010.html Sunnyvale, CA - Unidym, a majority owned subsidiary of Arrowhead Research (NASDAQ: ARWR), announced today that it has entered an agreement with global glass manufacturer Guardian Industries to develop and commercialize carbon coated glass products for touch screen devices and other applications. Wed, 19 May 2010 11:20:00 PST http://www.arrowheadresearch.com/publications/may13_2010.html PASADENA, Calif. – Arrowhead Research Corporation (NASDAQ: ARWR)today announced financial results for its fiscal 2010 second quarter ended March 31, 2010. Thu, 13 May 2010 12:00:00 PST http://www.arrowheadresearch.com/pdf/Arrowhead-Fortune_May_2010.pdf As seen in Fortune, May 24, 2010 issue Thu, 13 May 2010 11:00:00 PST http://www.arrowheadresearch.com/publications/may7_2010.html PASADENA, Calif. — May 7, 2010 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2010 second quarter ended March 31, 2010, on Thursday, May 13, 2010, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Fri, 7 May 2010 6:00:00 PST http://www.arrowheadresearch.com/publications/april26_2010.html PASADENA, Calif.—April 26, 2010—Arrowhead Research Corporation (Nasdaq: ARWR) announced today the appointment of Dr. Andrew von Eschenbach to its Scientific Advisory Board (SAB). Mon, 26 April 2010 12:00:00 PST http://www.arrowheadresearch.com/publications/april20_2010.html PASADENA, Calif.—April 20, 2010—Arrowhead Research Corporation (Nasdaq: ARWR) announced today that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the following investor conferences Tue, 20 April 2010 12:30:00 PST http://www.arrowheadresearch.com/publications/april15_2010.html PASADENA, Calif. – April 15, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on April 14, 2010, it received a notification from the NASDAQ Stock Market indicating that the Company has regained compliance with NASDAQ Rule 5550(a)(2) in that the Company's closing bid price has been at $1.00 per share or greater for at least 10 consecutive business days. Thu, 15 April 2010 12:00:00 PST http://www.arrowheadresearch.com/publications/april12_2010.html Sunnyvale, CA — Unidym, a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that touch sensitive MP-4 players enabled by Unidym’s transparent conductive films were displayed at the 75th China Electronics Fair. Mon, 12 April 2010 12:30:00 PST http://www.arrowheadresearch.com/publications/april7_2010.html PASADENA, Calif.—April 7, 2010—Arrowhead Research Corporation (Nasdaq: ARWR) announced today the appointment of Dr. Lee Hartwell to its Scientific Advisory Board. Wed, 7 April 2010 11:10:00 PST http://www.arrowres.com/pdf/Arrowhead_ProdDev_040510.pdf The publication of data from a Phase I trial of CALAA-01 provided the first proof of concept in man that systemically delivered short interfering RNA can be targeted to specific cells. Mon, 5 April 2010 12:10:00 PST http://www.arrowres.com/pdf/CalandoReport.pdf CALAA-01 Results Show Delivery Technology to Meet Critical Need in RNAi Therapeutics, Putting Arrowhead in Position to Monetize Asset. Mon, 5 April 2010 12:05:00 PST http://www.arrowres.com/publications/march22_2010.html <p>PASADENA, Calif. – March 22, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc. has demonstrated systemic delivery of siRNA and the successful "silencing" of a widely recognized cancer gene via RNA interference (RNAi) in humans.</p> Mon, 22 March 2010 11:00:00 PST http://media.caltech.edu/press_releases/13334 PASADENA, Calif.—A California Institute of Technology (Caltech)-led team of researchers and clinicians has published the first proof that a targeted nanoparticle—used as an experimental therapeutic and injected directly into a patient’s bloodstream—can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi). Sun, 21 March 2010 12:20:00 PST http://www.arrowres.com/publications/march19_2010.html <p>PASADENA, Calif. – March 18, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on March 16, 2010, it received a notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, until September 13, 2010, to regain compliance with NASDAQ's $1.00 minimum bid requirement.</p> Tue, 18 March 2010 11:40:00 PST http://www.arrowres.com/publications/february11_2010.html <p>PASADENA, Calif. – Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 first quarter ended December 31, 2009.</p> Tue, 11 Febr 2010 12:00:00 PST http://www.arrowres.com/publications/february08_2010.html <p>PASADENA, Calif. - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2010 first quarter ended December 31, 2009, on Thursday, February 11, 2009 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 877-941-4774 or 480-629-9760. Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com.</p> Mon, 08 Febr 2010 10:00:00 PST http://www.arrowres.com/publications/february08_2010_unidym.html <p>Sunnyvale, CA - Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that Malcolm Gillis, Ph.D. has been appointed to its Board of Directors. Dr. Gillis served as the President of William Marsh Rice University from 1993 until 2004 and guided Rice to become a leader in the then emerging field of nanoscience. His distinguished academic career focused on economics and environmental public policy and included appointments at Duke University and Harvard University.</p> Mon, 08 Febr 2010 12:10:00 PST http://www.arrowres.com/publications/february02_2010.html <p>PASADENA, Calif. - February 2, 2010 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope's lead compound for cartilage regeneration. The study's authors, which include Nanotope co-founder Dr. Samuel Stupp, showed that Nanotope's bioactive nanofiber system promotes the growth of new cartilage in a rabbit model.</p> Tue, 02 Febr 2010 11:30:00 PST http://www.arrowres.com/publications/fabruary02_2010.html <p>Sunnyvale, CA – Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has signed a definitive agreement to create a joint venture partnership with Wisepower, a publicly traded Korean company (KOSDAQ: 040670), to market and co-develop Unidym’s proprietary film and electronic ink products into the Korean touch panel and display industries.</p> Mon, 01 Febr 2010 12:40:00 PST http://www.arrowres.com/publications/jan20.html <p>Sunnyvale, CA – Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has completed three licensing agreements for its nanotechnology intellectual property (IP) for use in applications such as aerospace and military products.</p> Wed, 20 Jan 2010 11:00:00 PST